IGFBP2 and prostate carcinoma: Additionally, it has been demonstrated that the expression levels of PTEN and IGFBP2 are inversely correlated in human brain and prostate cancers, and it was suggested that IGFBP2 is a potential serum biomarker of PTEN status and PI3K/AKT pathway activation in patients with cancer [49].